Same here just filter this clown |
To be clear, the Grant rns from a MONTH ago. No newsflow over the past week to justify a 50% rise in mcap over the past week.
The Grant provides Fusion with access to:
· approximately £1m of direct non-dilutive funding for research & development initiatives;
· up to £5m of capital equipment;
· approximately 20 core staff, laboratories and offices spaces; and
· new PhD studentships.
"It is intended that the non-dilutive funding available under the Grant will be used by Fusion to cover human resource needs, materials/consumables costs and capital investment. As such the bulk of the non-dilutive funding is likely to be claimed in the earlier period of the Grant and is expected to be paid quarterly in advance against an agreed project plan, which is a further distinct advantage to the consortium members including Fusion. The project is due to start on 1st January 2025." |
We should be hearing about the proposed alliance with NCI this month. Trading update and trigger pulled on the grant to drive much larger contracts. Can't see past this share. Also their AI technology is well advanced and AI can command a serious multiple . Love it |
We should be hearing about the proposed alliance with NCI this month. Trading update and trigger pulled on the grant to drive much larger contracts. Can't see past this share. Also their AI technology is well advanced and AI can command a serious multiple . Love it |
PS,
"So the price can rise and fall substantially due to this issue."
That's exactly my point. Hundreds of trades, grouped together and price rises substantially. Works both ways.
Agree, we agree to disagree. Let's see what the company newsflow is. |
Typo Correction *due to the number of shares in issue not just to the number of shares in issue |
This is a very small company with a relatively small market capitalisation of approx 9 to 10 million pounds so shares are difficult to trade and can usually only be purchased in small amounts just to the number of shares in issue. So the price can rise and fall substantially due to this issue.This was 150 pence per share 5 years ago and fell due to placings and dilution etc and after the Covid sentiment had passed and I'm sure for many other reasons.I see the rise this last number of weeks as more to do with positive sentiment and future confidence whereas you see it as a pump and dump so we will agree to disagree. |
PS
"But when the share price was falling no one really questioned that"
I wasn't aware of it.
"now that it’s rising you think it too good be to true. Why?"
I'm saying it's a pump and dump. Look at the trades last week. Hundreds of them, grouped and timed. There aren't hundreds of PIs, are there? Look at the number of posters
The Grant rns and interims were over a month ago. The rise early Dec was more likely due to those.
I'm questioning the rise over the past week. |
Just filter PS. A well known clown / Troll. |
Charts are all well and good but look at the fundamentals of this Business. Groundbreaking AI fusion Antibody technology which is similar to a peer in the USA which is worth over $300m. FAB fell from one pound to 4p during the pandemic but management have guided it through to this point. New contract wins at higher margins will keep coming thanks to the 20 free staff included in the grant. The 20 staff resources will allowFusion to secure bigger contracts , enjoy bigger margins and execute in record time. The company is also looking at licensing deals with big pharmaceutical players. However, current shareholders are unlikely to see the full benefits of this exciting company as fusion is a sitting duck at 10m valuation when you compare to our US peers. |
AIM weekly movers: Fusion Antibodies chart indicates rise
"Clinical antibodies supplier Fusion Antibodies (LON: FAB) was highlighted by Zak Myr on his Bulletin Board Heroes broadcast on Thursday. According to his assessment of the chart he was targeting 9.25p by the end of January. He said that the next major resistance point is 10p. There were 3.1 million shares traded on Thursday and on Friday. The share price was 45% higher at 10.15p, which suggests that there could be further improvement." |
Why do u say that? I'd be interested to hear what makes you think that. |
Not a typical AIM share as not a large amount of shares in circulation, this makes it difficult to buy and sell at times so making it hard for the traders to manipulate Any news could send this much higher. Company seems to have a good recovery plan and so worth a punt but don't invest your life savings just in case |
Quite the opposite actually- world class management team . Only top drawer management teams can secure 6 million pound grants. No go shuffle off to vanquis |
Management are scumbag ... will bankrupt all investors |
You are very welcome to your view Sikh and it's always good to have opposing views on boards. But when the share price was falling no one really questioned that either and now that it's rising you think it too good be to true. Why?There will always be pumpers and dumpers but i am in for the long haul and I am happy and confident in my decision. You are more than capable of making your own mind up so I won't slate you whatever you decide |
Take a lie down over the weekend bud. You've had a stressful day trying to grasp fusion . |
ImDandy
"Latest house broker conclusion written a few weeks ago."
That's my point, few weeks ago. In fact a month since the Grant rns.
The shares have already more than doubled since start of Dec.
There's nothing since to backup why they have risen sharply this week. |
Take a couple of nurofen mate. You clearly know nothing about this company. That's obvious |
Take a break mste |
Look at the trades, grouped together and traded within a few secs... That pushes the share price higher. It's not genuine investors but traders.
Exactly same happens on others which were pumped/dumped.
I bought a few today for the same reason as Byot and Trmr(now nexn).. It is being pumped/dumped. Again, I'll try and sell before the p&d gang do!!
Byot - now delisted.
and Trmr (now nexn).
According to some posters, there's supposedly a TU due.
Let's see what the company has to say.
Best to trade |
Read this over the weekend. Latest house broker conclusion written a few weeks ago. Fusion's market capitalisation is £4.3m, suggesting an EV of £3.9m. We consider this to represent a geared situation tied to the success of Fusion's recovery plan, given almost no value is being ascribed to its class leading antibody discovery technologies. Given there is evidence of a turnaround in its fortunes and that sales and margins are on an upward trajectory, our investment thesis is that investors will start to recognise the value inherent in Fusion's class leading antibody discovery technology. To highlight this, we would draw attention to the valuation of Absci (Nasdaq: ABSI), an albeit much-larger US/Canadian-based firm that has an AI-led approach to antibody drug design. This company has a market capitalisation of $447m and cash of $145m, hence an EV of $302m. |
I must admit that it's always amusing that a few envious clowns never fail to try and embarrass themselves. Usually quite successfully lol. |
Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
Hot Features
Premium
